Ximerex, Inc. is an early stage biotechnology company developing xenotransplantation for the treatment of heart, kidney, liver disease and diabetes. Organ transplants provide effective life support for patients with organ failure; however, a severe shortage of human donors leaves a large unmet need. Ximerex has proprietary technology to allow the survival of pig organ transplants. Using an exceptionally clean herd of biomedical grade swine as a source of transplanted organs, Ximerex is preparing to save lives and improve the quality of life for thousands in the U.S. and beyond.